Comparative study of a single lead ECG in a wearable device.

BACKGROUND: Technological advances have led to electrocardiograph (ECG) functionality becoming increasingly accessible in wearable health devices, which has the potential to vastly expand the clinician's ability to monitor, diagnose, and manage cardiac health conditions. However, achieving the high signal quality necessary to make an accurate and confident diagnosis is inherently challenging on consumer device-acquired ECGs. Effective signal conditioning is crucial to make ECG data from wearable devices clinically actionable. OBJECTIVE: This study evaluates the heart rate (HR) performance of ECG data collected on the HeartKey® Test Watch, a single lead, dry electrode wrist wearable, against data acquired on two criterion devices: the Bittium® Faros 180, a gold standard wet electrode ambulatory monitoring device, and the HeartKey Chest Module. METHODS: ECG data was simultaneously acquired on three devices during a multi-stage protocol (sitting, walking, standing) designed to reflect the motion noise of real-life scenarios. Raw ECGs from the HeartKey Test Watch and HeartKey Chest Module were processed through HeartKey software, and the accuracy of the outputted heart rate data was compared to that of the criterion device at each stage of the protocol. A beat rejection analysis was performed to provide insight into the degree of high-frequency noise present in ECGs recorded on the HeartKey Test Watch. RESULTS: Data acquired on the HeartKey Test Watch and processed by HeartKey software generated HR metrics that closely matched that of the criterion devices throughout the protocol. Bland-Altman analysis showed a mean absolute HR difference of 0.74, 1.21, 0.80 bpm during the sitting, walking, and standing stages respectively, which is within the ± 10% or ±5 bpm range required by ANSI EC13. ECG data from the HeartKey Test Watch had a higher beat rejection rate relative to the HeartKey Chest Module (8.5% vs ∼0%) due to the excessive high-frequency noise generated during the motion-based protocol. CONCLUSION: HeartKey software demonstrated highly accurate HR performance, comparable to that of the criterion Faros device, when processing challenging ECG data acquired on a single lead, dry electrode wrist wearable during both non-motion and motion-based protocols.

A universal, high-performance ECG signal processing engine to reduce clinical burden.

BACKGROUND: Electrocardiogram (ECG) signal conditioning is a vital step in the ECG signal processing chain that ensures effective noise removal and accurate feature extraction. OBJECTIVE: This study evaluates the performance of the FDA 510 (k) cleared HeartKey Signal Conditioning and QRS peak detection algorithms on a range of annotated public and proprietary ECG databases (HeartKey is a UK Registered Trademark of B-Secur Ltd). METHODS: Seven hundred fifty-one raw ECG files from a broad range of use cases were individually passed through the HeartKey signal processing engine. The algorithms include several advanced filtering steps to enable significant noise removal and accurate identification of the QRS complex. QRS detection statistics were generated against the annotated ECG files. RESULTS: HeartKey displayed robust performance across 14 ECG databases (seven public, seven proprietary), covering a range of healthy and unhealthy patient data, wet and dry electrode types, various lead configurations, hardware sources, and stationary/ambulatory recordings from clinical and non-clinical settings. Over the NSR, MIT-BIH, AHA, and MIT-AF public databases, average QRS Se and PPV values of 98.90% and 99.08% were achieved. Adaptable performance (Se 93.26%, PPV 90.53%) was similarly observed on the challenging NST database. Crucially, HeartKey's performance effectively translated to the dry electrode space, with an average QRS Se of 99.22% and PPV of 99.00% observed over eight dry electrode databases representing various use cases, including two challenging motion-based collection protocols. CONCLUSION: HeartKey demonstrated robust signal conditioning and QRS detection performance across the broad range of tested ECG signals. It should be emphasized that in no way have the algorithms been altered or trained to optimize performance on a given database, meaning that HeartKey is potentially a universal solution capable of maintaining a high level of performance across a broad range of clinical and everyday use cases.

Real-world insight into public access defibrillator use over five years.

BACKGROUND: Public access defibrillators (PADs) represent unique life-saving medical devices as they may be used by untrained lay rescuers. Collecting representative clinical data on these devices can be challenging. Here, we present results from a retrospective observational cohort study, describing real-world PAD utilisation over a 5-year period. METHODS: Data were collected between October 2012 and October 2017. Responders voluntarily submitted electronic data downloaded from HeartSine PADs, and patient demographics and other details using a case report form in exchange for a replacement battery and electrode pack. RESULTS: Data were collected for 977 patients (692 males, 70.8%; 255 females, 26.1%; 30 unknown, 3.1%). The mean age (SD) was 59 (18) years (range <1 year to 101 years). PAD usage occurred most commonly in homes (n=328, 33.6%), followed by public places (n=307, 31.4%) and medical facilities (n=128, 13.1%). Location was unknown in 40 (4.09%) events. Shocks were delivered to 354 patients. First shock success was 312 of 350 patients where it could be determined (89.1%, 95% CI 85.4% to 92.2%). Patients with reported response times ≤5 min were more likely to survive to hospital admission (89/296 (30.1%) vs 40/250 (16.0%), p<0.001). Response time was unknown for 431 events. CONCLUSION: This is the first study to report global PAD usage in voluntarily submitted, unselected real-world cases and demonstrates the real-world effectiveness of PADs, as confirmed by first shock success.